

Biocatalysis

A. S. Bommarius, B. R. Riebel



WILEY-
VCH

WILEY-VCH Verlag GmbH & Co. KGaA

Biocatalysis

A. S. Bommarius, B. R. Riebel

Related Titles

S. Brakmann, K. Johnsson

Directed Molecular Evolution of Proteins

or How to Improve Enzymes for Biocatalysis

February 2002

ISBN 3-527-30423-1

M. C. Flickinger, S. W. Drew

Encyclopedia of Bioprocess Technology

Fermentation, Biocatalysis, and Bioseparation

April 1999

ISBN 0-471-13822-3

I. T. Horvath

Encyclopedia of Catalysis

6 Volume Set

February 2003

ISBN 0-471-24183-0

S. M. Roberts, G. Casy, M.-B. Nielsen, S. Phythian,
C. Todd, U. Wiggins

Biocatalysts for Fine Chemicals Synthesis

October 1999

ISBN 0-471-97901-5

K. Drauz, H. Waldmann

Enzyme Catalysis in Organic Synthesis

A Comprehensive Handbook

April 2002

ISBN 3-527-29949-1

U. T. Bornscheuer, R. J. Kazlauskas

Hydrolases in Organic Synthesis

Regio- and Stereoselective Biotransformations

October 1999

ISBN 3-527-30104-6

B. Cornils, W. A. Herrmann, R. Schlögl, C.-H. Wong

Catalysis from A to Z

A Concise Encyclopedia

March 2000

ISBN 3-527-29855-X

Biocatalysis

A. S. Bommarius, B. R. Riebel



WILEY-
VCH

WILEY-VCH Verlag GmbH & Co. KGaA

Prof. Dr. Andreas Sebastian Bommarius

School of Chemical and Biomolecular
Engineering
Parker H. Petit Biotechnology Institute
Georgia Institute of Technology
315 Ferst Drive, N. W.
Atlanta, GA 30332-0363
USA

Dr. Bettina Riebel

Emory University School of Medicine
Whitehead Research Building
615 Michael Street
Atlanta, GA 30322
USA

■ This book was carefully produced. Nevertheless, authors and publisher do not warrant the information contained therein to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.: applied for

A catalogue record for this book is available from the British Library.

Bibliographic information published by

Die Deutsche Bibliothek

Die Deutsche Bibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the internet at <http://dnb.ddb.de>.

© 2004 Wiley-VCH Verlag GmbH & Co.
KGaA, Weinheim

All rights reserved (including those of translation in other languages). No part of this book may be reproduced in any form – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Printed in the Federal Republic of Germany.
Printed on acid-free paper.

Composition Manuela Treindl, Laaber

Printing betz-druck GmbH, Darmstadt

Bookbinding Großbuchbinderei J. Schäffer
GmbH & Co. KG, Grünstadt

ISBN 3-527-30344-8

Preface

The field of biocatalysis is at a crossroads. On one hand, the frontier of research races ahead, propelled by advances in the database-supported analysis of sequences and structures as well as the designability of genes and proteins. Moreover, the “design rules” for biocatalysts have emerged from vague images on the horizon, to come into much clearer view. On the other hand, experienced practitioners from other areas as well as more and more students entering this field search for ways to obtain the level of knowledge in biocatalysis that advances their own agenda. However, both groups find a rapidly growing field with too little *guidance* towards the research front and too little *structure* in its guiding principles. In this situation, this book seeks to fill the gap between the research front and the area beyond basic courses in biochemistry, organic synthesis, molecular biology, kinetics, and reaction engineering. Students and practitioners alike are often left alone to bridge the gulf between basic textbooks and original research articles; this book seeks to cover this intermediate area.

Another challenge this book strives to address results from the interdisciplinary nature of the field of biocatalysis. Biocatalysis is a synthesis of chemistry, biology, chemical engineering, and bioengineering, but most students and practitioners enter this field with preparation essentially limited to one of the major contributing areas, or at best two. The essence of biocatalysis, as well as most of its current research, however, is captured in the interdisciplinary overlap between individual areas. Therefore, this work seeks to help readers to combine their prior knowledge with the contents and the methods in this book to make an integrated whole.

The book is divided into three parts:

- Chapters 1 through 7 cover *basic tools*. Many readers have probably encountered the contents of some chapters before; nevertheless, we hope to offer an update and a fresh view.
- Chapters 8 through 14 expand on *advanced tools*. While command of such advanced concepts is indispensable in order to follow, much less to lead, today’s developments in biocatalysis, the mastering of such concepts and tools cannot necessarily be expected of all practitioners in the field, especially if their major course of study often did not even touch on such topics.
- Chapters 15 through 20 treat *applications* of all the tools covered in previous chapters. “Applications” here encompass not just industrial-scale realization of bio-

catalysis but also new intellectual frontiers in biological catalysis that are possible with today's technologies, such as rapidly expanding DNA databases or comprehensive coverage of three-dimensional structure analysis for many enzymes.

In the early part of the book, several chapters have a fairly clear emphasis on chemistry, biology, or chemical engineering. Chapters on the isolation of microorganisms (Chapter 3), molecular biology tools (Chapter 4), protein engineering (Chapter 10), or directed evolution (Chapter 11) have a distinct biological flavor. Chemistry is the main topic in the chapters on applications of enzymes as products (Chapter 6), in bulk and fine chemicals (Chapter 7), and in pharmaceuticals (Chapter 13). Chemical engineering concepts predominate in the chapters on biocatalytic reaction engineering (Chapter 5) or on processing steps for enzyme manufacture (Chapter 8). Other chapters contribute a perspective from biochemistry/enzymology, such as characterization of biocatalysts (Chapter 2) and methods of studying proteins (Chapter 9), or from informatics, most notably bioinformatics (Chapter 14).

Finally, a word on the history of this book: the idea for the present work originated during a lectureship of one of us (A.S.B.) as an adjunct faculty member at the Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen in Aachen, Germany, for nine years while he was working at Degussa in Wolfgang, Germany. Time and time again, students enjoyed the interdisciplinary nature and coverage of biocatalysis but lacked adequate preparation in those basic tools that were not provided during their courses for their respective major, be it chemistry, biology, or chemical engineering. Similar observations were made when teaching biocatalysis or related subjects at the Georgia Institute of Technology in Atlanta/GA, USA. One of the aims of this book is to take readers back to scientific fundamentals often long forgotten, to let them to participate in the joy of discovery and understanding stemming from a multi-faceted picture of nature. While scientific fundamentals are a source of immense satisfaction, applications with an impact in the day-to-day world are just as important. Two of the biggest challenges facing mankind today (and not exclusively the industrial societies) are maintenance and improvement of *human health*, and maintenance and improvement of *the environment*. Biocatalysis aids the first of these goals through its selectivity in generating ever more complex pharmaceutically active molecules, and the second goal by opening new routes to both basic and performance chemicals with the aim of achieving sustainable development.

We hope that you enjoy reading this book. We encourage you to contact us to voice your opinion, gripe, laud, discuss aspects of the book, point out errors or ambiguities, make suggestions for improvements, or just to let us know what you think. The easiest way to do this is via email at bommariu@bellsouth.net or andreas.bommarius@alum.mit.edu.

We wish you pleasant reading.

Andreas S. Bommarius and Bettina R. Riebel
Atlanta/GA, USA
December 2003

Acknowledgments

For more than a decade, one of us (A.S.B.) had the good fortune to be associated with Degussa, one of the early players, and currently still strong, in the area of biocatalysis, in its R&D center in Wolfgang, Germany. While several factors were responsible for Degussa's venture into biocatalysis, certainly the most influential was the steadfast support of biocatalysis by Degussa's former board member and Head of Research, Professor Heribert Offermanns. His unconventional and far-sighted way of thinking remains an example and A.S.B. thanks him warmly for his attitude and encouragement. A.S.B. is also grateful to Professor Karlheinz Drauz, himself an accomplished author with Wiley-VCH, for sustained support and also for supporting biocatalysis at Degussa during difficult times. A.S.B. also fondly remembers co-workers at Degussa and its many subsidiaries. He thanks Wolfgang Leuchtenberger, his predecessor and representing a group too numerous to acknowledge individually, and encourages Harald Gröger, his successor.

The origin of this book stems from a biweekly lectureship that A.S.B. held at the RWTH Aachen (in Aachen, Germany) from 1991 to 2000, first at the Institute of Biotechnology under the late Harald Voss, then in the Institute of Technical Chemistry and Petroleum Chemistry under Wilhelm Keim. A.S.B. expressly thanks Wilhelm Keim for his continued support and advice, not just with the lectureship but also during his habilitation.

Both of us have several reasons to thank Professors Maria-Regina Kula at the University of Düsseldorf, Germany, and Christian Wandrey at the Research Center Jülich, Germany. While both of them have left a huge impact on the field of biocatalysis in general (acknowledged, among other honors, by the German Technology Transfer Prize in 1983 and the Enzyme Engineering Award in 1995 to both of them), they influenced each of us markedly. One of us (B.R.R.) thanks her advisor Maria-Regina Kula and, specifically, her direct mentor, Werner Hummel, for sustained support and interest during her formative thesis years and beyond. A.S.B. gladly acknowledges both of them and Christian Wandrey for many years of fruitful collaboration. The impact of their views on both of us is evident in many parts of this book.

One of us (A.S.B.) gratefully acknowledges the support from Georgia Tech, from the higher administration to the laboratory group, for getting his own research group started. As representatives for a much more numerous group, A.S.B. thanks Dr. Ronald Rousseau, his School Chair, himself an author of one of the most influ-

ential textbooks on chemical engineering, for his trust and his support of the area of biocatalysis in chemical engineering, as well as Dr. Phillip Gibbs, his first postdoctoral associate, for countless discussions on the research front in the field.

We thank our publisher, Wiley-VCH, in Weinheim, Germany, for their continual support and enthusiasm. The publishing team, including Karin Dembowski, Andrea Pillmann, Eva Wille, Karin Proff, and Hans-Jochen Schmitt, had to put up with quite a scheduling challenge, not to mention the pain resulting from the need for both authors to relocate to Atlanta/GA, USA, and establish their careers there. Both of us thank the publishers for exemplary support and the high quality of workmanship reflected in the layout of this book.

Last but not least, we could write this book because we enjoyed countless interactions with other scientists and engineers who shaped our view of the field of biocatalysis. A representative, but certainly not exhaustive, list of these individuals, besides those already mentioned above, includes Frances Arnold, Uwe Bornscheuer, Stefan Buchholz, Mark Burk, Robert DiCosimo, David Dodds, Franz Effenberger, Uwe Eichhorn, Wolfgang Estler, Andreas Fischer, Tomas Hudlicky, Hans-Dieter Jakubke, Andreas Karau, Alexander Klibanov, Andreas Liese, Oliver May, Jeffrey Moore, Rainer Müller, Mark Nelson, David Rozzell, Roger Sheldon, Christoph Syldatk, Stefan Verseck, and George Whitesides. We thank all of them for their contribution to our view of the field.

Andreas S. Bommarius and Bettina R. Riebel
Atlanta/GA, USA
December 2003

Contents

Preface V

Acknowledgments VII

1	Introduction to Biocatalysis	1
1.1	Overview: The Status of Biocatalysis at the Turn of the 21st Century	2
1.1.1	State of Acceptance of Biocatalysis	2
1.1.2	Current Advantages and Drawbacks of Biocatalysis	4
1.1.2.1	Advantages of Biocatalysts	4
1.1.2.2	Drawbacks of Current Biocatalysts	5
1.2	Characteristics of Biocatalysis as a Technology	6
1.2.1	Contributing Disciplines and Areas of Application	6
1.2.2	Characteristics of Biocatalytic Transformations	7
1.2.2.1	Comparison of Biocatalysis with other Kinds of Catalysis	8
1.2.3	Applications of Biocatalysis in Industry	9
1.2.3.1	Chemical Industry of the Future: Environmentally Benign Manufacturing, Green Chemistry, Sustainable Development in the Future	9
1.2.3.2	Enantiomerically Pure Drugs or Advanced Pharmaceutical Intermediates (APIs)	10
1.3	Current Penetration of Biocatalysis	11
1.3.1	The Past: Historical Digest of Enzyme Catalysis	11
1.3.2	The Present: Status of Biocatalytic Processes	11
1.4	The Breadth of Biocatalysis	14
1.4.1	Nomenclature of Enzymes	14
1.4.2	Biocatalysis and Organic Chemistry, or “Do we Need to Forget our Organic Chemistry?”	14
2	Characterization of a (Bio-)catalyst	19
2.1	Characterization of Enzyme Catalysis	20
2.1.1	Basis of the Activity of Enzymes: What is Enzyme Catalysis?	20
2.1.1.1	Enzyme Reaction in a Reaction Coordinate Diagram	21
2.1.2	Development of Enzyme Kinetics from Binding and Catalysis	21

2.2	Sources and Reasons for the Activity of Enzymes as Catalysts	23
2.2.1	Chronology of the Most Important Theories of Enzyme Activity	23
2.2.2	Origin of Enzymatic Activity: Derivation of the Kurz Equation	24
2.2.3	Consequences of the Kurz Equation	25
2.2.4	Efficiency of Enzyme Catalysis: Beyond Pauling's Postulate	28
2.3	Performance Criteria for Catalysts, Processes, and Process Routes	30
2.3.1	Basic Performance Criteria for a Catalyst: Activity, Selectivity and Stability of Enzymes	30
2.3.1.1	Activity	30
2.3.1.2	Selectivity	31
2.3.1.3	Stability	32
2.3.2	Performance Criteria for the Process	33
2.3.2.1	Product Yield	33
2.3.2.2	(Bio)catalyst Productivity	34
2.3.2.3	(Bio)catalyst Stability	34
2.3.2.4	Reactor Productivity	35
2.3.3	Links between Enzyme Reaction Performance Parameters	36
2.3.3.1	Rate Acceleration	36
2.3.3.2	Ratio between Catalytic Constant k_{cat} and Deactivation Rate Constant k_{d}	38
2.3.3.3	Relationship between Deactivation Rate Constant k_{d} and Total Turnover Number TTN	38
2.3.4	Performance Criteria for Process Schemes, Atom Economy, and Environmental Quotient	39
3	Isolation and Preparation of Microorganisms	43
3.1	Introduction	44
3.2	Screening of New Enzyme Activities	46
3.2.1	Growth Rates in Nature	47
3.2.2	Methods in Microbial Ecology	47
3.3	Strain Development	48
3.3.1	Range of Industrial Products from Microorganisms	48
3.3.2	Strain Improvement	50
3.4	Extremophiles	52
3.4.1	Extremophiles in Industry	54
3.5	Rapid Screening of Biocatalysts	56
4	Molecular Biology Tools for Biocatalysis	61
4.1	Molecular Biology Basics: DNA versus Protein Level	62
4.2	DNA Isolation and Purification	65
4.2.1	Quantification of DNA/RNA	66
4.3	Gene Isolation, Detection, and Verification	67
4.3.1	Polymerase Chain Reaction	67
4.3.2	Optimization of a PCR Reaction	69
4.3.3	Special PCR Techniques	71

4.3.3.1	Nested PCR	71
4.3.3.2	Inverse PCR	71
4.3.3.3	RACE: Rapid Amplification of cDNA Ends	71
4.3.4	Southern Blotting	74
4.3.4.1	Probe Design and Labeling	76
4.3.4.2	Hybridization	76
4.3.4.3	Detection	76
4.3.5	DNA-Sequencing	77
4.4	Cloning Techniques	77
4.4.1	Restriction Mapping	78
4.4.2	Vectors	78
4.4.3	Ligation	80
4.4.3.1	Propagation of Plasmids and Transformation in Hosts	81
4.5	(Over)expression of an Enzyme Function in a Host	81
4.5.1	Choice of an Expression System	81
4.5.2	Translation and Codon Usage in <i>E. coli</i>	82
4.5.3	Choice of Vector	84
4.5.3.1	Generation of Inclusion Bodies	85
4.5.3.2	Expression of Fusion Proteins	85
4.5.3.3	Surface Expression	87
4.5.4	Expression of Eukaryotic Genes in Yeasts	87
5	Enzyme Reaction Engineering	91
5.1	Kinetic Modeling: Rationale and Purpose	92
5.2	The Ideal World: Ideal Kinetics and Ideal Reactors	94
5.2.1	The Classic Case: Michaelis–Menten Equation	94
5.2.2	Design of Ideal Reactors	96
5.2.3	Integrated Michaelis–Menten Equation in Ideal Reactors	96
5.2.3.1	Case 1: No Inhibition	97
5.3	Enzymes with Unfavorable Binding: Inhibition	97
5.3.1	Types of Inhibitors	97
5.3.2	Integrated Michaelis–Menten Equation for Substrate and Product Inhibition	99
5.3.2.1	Case 2: Integrated Michaelis–Menten Equation in the Presence of Substrate Inhibitor	99
5.3.2.2	Case 3: Integrated Michaelis–Menten Equation in the Presence of Inhibitor	99
5.3.3	The $K_I - [I]_{50}$ Relationship: Another Useful Application of Mechanism Elucidation	103
5.4	Reactor Engineering	105
5.4.1	Configuration of Enzyme Reactors	105
5.4.1.1	Characteristic Dimensionless Numbers for Reactor Design	107
5.4.2	Immobilized Enzyme Reactor (Fixed-Bed Reactor with Plug-Flow)	108
5.4.2.1	Reactor Design Equations	108
5.4.2.2	Immobilization	109

5.4.2.3	Optimal Conditions for an Immobilized Enzyme Reactor	110
5.4.3	Enzyme Membrane Reactor (Continuous Stirred Tank Reactor, CSTR)	110
5.4.3.1	Design Equation: Reactor Equation and Retention	110
5.4.3.2	Classification of Enzyme Membrane Reactors	111
5.4.4	Rules for Choice of Reaction Parameters and Reactors	113
5.5	Enzyme Reactions with Incomplete Mass Transfer: Influence of Immobilization	113
5.5.1	External Diffusion (Film Diffusion)	114
5.5.2	Internal Diffusion (Pore Diffusion)	114
5.5.3	Methods of Testing for Mass Transfer Limitations	116
5.5.4	Influence of Mass Transfer on the Reaction Parameters	118
5.6	Enzymes with Incomplete Stability: Deactivation Kinetics	119
5.6.1	Resting Stability	119
5.6.2	Operational Stability	120
5.6.3	Comparison of Resting and Operational Stability	122
5.6.4	Strategy for the Addition of Fresh Enzyme to Deactivating Enzyme in Continuous Reactors	124
5.7	Enzymes with Incomplete Selectivity: E-Value and its Optimization	126
5.7.1	Derivation of the E-Value	126
5.7.2	Optimization of Separation of Racemates by Choice of Degree of Conversion	128
5.7.2.1	Optimization of an Irreversible Reaction	128
5.7.2.2	Enantioselectivity of an Equilibrium Reaction	129
5.7.2.3	Determination of Enantiomeric Purity from a Conversion–Time Plot	130
5.7.3	Optimization of Enantiomeric Ratio E by Choice of Temperature	130
5.7.3.1	Derivation of the Isoinversion Temperature	130
5.7.3.2	Example of Optimization of Enantioselectivity by Choice of Temperature	131
6	Applications of Enzymes as Bulk Actives:	
	Detergents, Textiles, Pulp and Paper, Animal Feed	135
6.1	Application of Enzymes in Laundry Detergents	136
6.1.1	Overview	136
6.1.2	Proteases against Blood and Egg Stains	138
6.1.3	Lipases against Grease Stains	139
6.1.4	Amylases against Grass and Starch Dirt	139
6.1.5	Cellulases	139
6.1.6	Bleach Enzymes	140
6.2	Enzymes in the Textile Industry: Stone-washed Denims, Shiny Cotton Surfaces	140
6.2.1	Build-up and Mode of Action of Enzymes for the Textile Industry	140
6.2.2	Cellulases: the Shinier Look	141

6.2.3	Stonewashing: Biostoning of Denim: the Worn Look	143
6.2.4	Peroxidases	144
6.3	Enzymes in the Pulp and Paper Industry: Bleaching of Pulp with Xylanases or Laccases	145
6.3.1	Introduction	145
6.3.2	Wood	146
6.3.2.1	Cellulose	146
6.3.2.2	Hemicellulose	147
6.3.2.3	Lignin	147
6.3.3	Papermaking: Kraft Pulping Process	149
6.3.4	Research on Enzymes in the Pulp and Paper Industry	150
6.3.4.1	Laccases	150
6.3.4.2	Xylanases	151
6.3.4.3	Cellulases in the Papermaking Process	152
6.4	Phytase for Animal Feed: Utilization of Phosphorus	152
6.4.1	The Farm Animal Business and the Environment	152
6.4.2	Phytase	153
6.4.3	Efficacy of Phytase: Reduction of Phosphorus	154
6.4.4	Efficacy of Phytase: Effect on Other Nutrients	155
7	Application of Enzymes as Catalysts: Basic Chemicals, Fine Chemicals, Food, Crop Protection, Bulk Pharmaceuticals	159
7.1	Enzymes as Catalysts in Processes towards Basic Chemicals	160
7.1.1	Nitrile Hydratase: Acrylamide from Acrylonitrile, Nicotinamide from 3-Cyanopyridine, and 5-Cyanovaleramide from Adiponitrile	160
7.1.1.1	Acrylamide from Acrylonitrile	160
7.1.1.2	Nicotinamide from 3-Cyanopyridine	162
7.1.1.3	5-Cyanovaleramide from Adiponitrile	162
7.1.2	Nitrilase: 1,5-Dimethyl-2-piperidone from 2-Methylglutaronitrile	163
7.1.3	Toluene Dioxygenase: Indigo or Prostaglandins from Substituted Benzenes via cis-Dihydrodiols	163
7.1.4	Oxynitrilase (Hydroxy Nitrile Lyase, HNL): Cyanohydrins from Aldehydes	167
7.2	Enzymes as Catalysts in the Fine Chemicals Industry	170
7.2.1	Chirality, and the Cahn–Ingold–Prelog and Pfeiffer Rules	170
7.2.2	Enantiomerically Pure Amino Acids	172
7.2.2.1	The Aminoacylase Process	172
7.2.2.2	The Amidase Process	174
7.2.2.3	The Hydantoinase/Carbamoylase Process	174
7.2.2.4	Reductive Amination of Keto Acids (L-tert-Leucine as Example)	177
7.2.2.5	Aspartase	180
7.2.2.6	L-Aspartate- β -decarboxylase	180
7.2.2.7	L-2-Aminobutyric acid	181
7.2.3	Enantiomerically Pure Hydroxy Acids, Alcohols, and Amines	182
7.2.3.1	Fumarase	182

7.2.3.2	Enantiomerically Pure Amines with Lipase	182
7.2.3.3	Synthesis of Enantiomerically Pure Amines through Transamination	183
7.2.3.4	Hydroxy esters with carbonyl reductases	185
7.2.3.5	Alcohols with ADH	186
7.3	Enzymes as Catalysts in the Food Industry	187
7.3.1	HFCS with Glucose Isomerase (GI)	187
7.3.2	Aspartame, Artificial Sweetener through Enzymatic Peptide Synthesis	188
7.3.3	Lactose Hydrolysis	191
7.3.4	“Nutraceuticals”: L-Carnitine as a Nutrient for Athletes and Convalescents (Lonza)	191
7.3.5	Decarboxylases for Improving the Taste of Beer	194
7.4	Enzymes as Catalysts towards Crop Protection Chemicals	195
7.4.1	Intermediate for Herbicides: (R)-2-(4-Hydroxyphenoxypropionic acid (BASF, Germany)	195
7.4.2	Applications of Transaminases towards Crop Protection Agents: L-Phosphinothricin and (S)-MOIPA	196
7.5	Enzymes for Large-Scale Pharma Intermediates	197
7.5.1	Penicillin G (or V) Amidase (PGA, PVA): β -Lactam Precursors, Semi-synthetic β -Lactams	197
7.5.2	Ephedrine	200
8	Biotechnological Processing Steps for Enzyme Manufacture	209
8.1	Introduction to Protein Isolation and Purification	210
8.2	Basics of Fermentation	212
8.2.1	Medium Requirements	213
8.2.2	Sterilization	214
8.2.3	Phases of a Fermentation	214
8.2.4	Modeling of a Fermentation	215
8.2.5	Growth Models	216
8.2.6	Fed-Batch Culture	216
8.3	Fermentation and its Main Challenge: Transfer of Oxygen	218
8.3.1	Determination of Required Oxygen Demand of the Cells	218
8.3.2	Calculation of Oxygen Transport in the Fermenter Solution	219
8.3.3	Determination of k_L , a , and $k_L a$	220
8.3.2.1	Methods of Measurement of the Product $k_L a$	221
8.4	Downstream Processing: Crude Purification of Proteins	223
8.4.1	Separation (Centrifugation)	223
8.4.2	Homogenization	225
8.4.3	Precipitation	226
8.4.3.1	Precipitation in Water-Miscible Organic Solvents	228
8.4.3.2	Building Quantitative Models for the Hofmeister Series and Cohn-Edsall and Setschenow Equations	228
8.4.4	Aqueous Two-Phase Extraction	229

8.5	Downstream Processing: Concentration and Purification of Proteins	231
8.5.1	Dialysis (Ultrafiltration) (adapted in part from Blanch, 1997)	231
8.5.2	Chromatography	233
8.5.2.1	Theory of Chromatography	233
8.5.2.2	Different Types of Chromatography	235
8.5.3	Drying: Spray Drying, Lyophilization, Stabilization for Storage	236
8.6	Examples of Biocatalyst Purification	237
8.6.1	Example 1: Alcohol Dehydrogenase [(R)-ADH from <i>L. brevis</i> (Riebel, 1997)]	237
8.6.2	Example 2: L-Amino Acid Oxidase from <i>Rhodococcus opacus</i> (Geueke 2002a,b)	238
8.6.3	Example 3: Xylose Isomerase from <i>Thermoanaerobium</i> Strain JW/SL-YS 489	240
9	Methods for the Investigation of Proteins	243
9.1	Relevance of Enzyme Mechanism	244
9.2	Experimental Methods for the Investigation of an Enzyme Mechanism	245
9.2.1	Distribution of Products (Curtin–Hammett Principle)	245
9.2.2	Stationary Methods of Enzyme Kinetics	246
9.2.3	Linear Free Enthalpy Relationships (LFERs): Brønsted and Hammett Effects	248
9.2.4	Kinetic Isotope Effects	249
9.2.5	Non-stationary Methods of Enzyme Kinetics: Titration of Active Sites	249
9.2.5.1	Determination of Concentration of Active Sites	249
9.2.6	Utility of the Elucidation of Mechanism: Transition-State Analog Inhibitors	251
9.3	Methods of Enzyme Determination	253
9.3.1	Quantification of Protein	253
9.3.2	Isoelectric Point Determination	254
9.3.3	Molecular Mass Determination of Protein Monomer: SDS-PAGE	254
9.3.4	Mass of an Oligomeric Protein: Size Exclusion Chromatography (SEC)	256
9.3.5	Mass Determination: Mass Spectrometry (MS) (after Kellner, Lottspeich, Meyer)	257
9.3.6	Determination of Amino Acid Sequence by Tryptic Degradation, or Acid, Chemical or Enzymatic Digestion	258
9.4	Enzymatic Mechanisms: General Acid–Base Catalysis	258
9.4.1	Carbonic Anhydrase II	258
9.4.2	Vanadium Haloperoxidase	260
9.5	Nucleophilic Catalysis	261
9.5.1	Serine Proteases	261
9.5.2	Cysteine in Nucleophilic Attack	265

9.5.3	Lipase, Another Catalytic Triad Mechanism	266
9.5.4	Metalloproteases	268
9.6	Electrophilic catalysis	269
9.6.1	Utilization of Metal Ions: ADH, a Different Catalytic Triad	269
9.6.1.1	Catalytic Mechanism of Horse Liver Alcohol Dehydrogenase, a Medium-Chain Dehydrogenase	269
9.6.1.2	Catalytic Reaction Mechanism of Drosophila ADH, a Short-Chain Dehydrogenase	271
9.6.2	Formation of a Schiff Base, Part I: Acetoacetate Decarboxylase, Aldolase	274
9.6.3	Formation of a Schiff Base with Pyridoxal Phosphate (PLP): Alanine Racemase, Amino Acid Transferase	275
9.6.4	Utilization of Thiamine Pyrophosphate (TPP): Transketolase	277
10	Protein Engineering	281
10.1	Introduction: Elements of Protein Engineering	282
10.2	Methods of Protein Engineering	283
10.2.1	Fusion PCR	284
10.2.2	Kunkel Method	285
10.2.3	Site-Specific Mutagenesis Using the QuikChange Kit from Stratagene	287
10.2.4	Combined Chain Reaction (CCR)	288
10.3	Glucose (Xylose) Isomerase (GI) and Glycoamylase: Enhancement of Thermostability	289
10.3.1	Enhancement of Thermostability in Glucose Isomerase (GI)	289
10.3.2	Resolving the Reaction Mechanism of Glucose Isomerase (GI): Diffusion-Limited Glucose Isomerase?	292
10.4	Enhancement of Stability of Proteases against Oxidation and Thermal Deactivation	293
10.4.1	Enhancement of Oxidation Stability of Subtilisin	293
10.4.2	Thermostability of Subtilisin	295
10.5	Creating New Enzymes with Protein Engineering	295
10.5.1	Redesign of a Lactate Dehydrogenase	295
10.5.2	Synthetic Peroxidases	297
10.6	Dehydrogenases, Changing Cofactor Specificity	298
10.7	Oxygenases	300
10.8	Change of Enantioselectivity with Site-Specific Mutagenesis	302
10.9	Techniques Bridging Different Protein Engineering Techniques	303
10.9.1	Chemically Modified Mutants, a Marriage of Chemical Modification and Protein Engineering	303
10.9.2	Expansion of Substrate Specificity with Protein Engineering and Directed Evolution	304
11	Applications of Recombinant DNA Technology: Directed Evolution	309
11.1	Background of Evolvability of Proteins	310

- 11.1.1 Purpose of Directed Evolution 310
- 11.1.2 Evolution and Probability 311
- 11.1.3 Evolution: Conservation of Essential Components of Structure 313
- 11.2 Process steps in Directed Evolution: Creating Diversity and Checking for Hits 314
 - 11.2.1 Creation of Diversity in a DNA Library 315
 - 11.2.2 Testing for Positive Hits: Screening or Selection 318
- 11.3 Experimental Protocols for Directed Evolution 319
 - 11.3.1 Creating Diversity: Mutagenesis Methods 319
 - 11.3.2 Creating Diversity: Recombination Methods 319
 - 11.3.2.1 DNA Shuffling 320
 - 11.3.2.2 Staggered Extension Process (StEP) 321
 - 11.3.2.3 RACHITT (Random Chimeragenesis on Transient Templates) 322
 - 11.3.3 Checking for Hits: Screening Assays 323
 - 11.3.4 Checking for Hits: Selection Procedures 324
 - 11.3.5 Additional Techniques of Directed Evolution 325
- 11.4 Successful Examples of the Application of Directed Evolution 325
 - 11.4.1 Application of Error-prone PCR: Activation of Subtilisin in DMF 325
 - 11.4.2 Application of DNA Shuffling: Recombination of p-Nitrobenzyl Esterase Genes 326
 - 11.4.3 Enhancement of Thermostability: p-Nitrophenyl Esterase 328
 - 11.4.4 Selection instead of Screening: Creation of a Monomeric Chorismate Mutase 329
 - 11.4.5 Improvement of Enantioselectivity: *Pseudomonas aeruginosa* Lipase 329
 - 11.4.6 Inversion of Enantioselectivity: Hydantoinase 330
 - 11.4.7 Redesign of an Enzyme's Active Site: KDPG Aldolase 331
- 11.5 Comparison of Directed Evolution Techniques 331
 - 11.5.1 Comparison of Error-Prone PCR and DNA Shuffling: Increased Resistance against Antibiotics 331
 - 11.5.2 Protein Engineering in Comparison with Directed Evolution: Aminotransferases 332
 - 11.5.2.1 Directed Evolution of Aminotransferases 332
 - 11.5.3 Directed Evolution of a Pathway: Carotenoids 333
- 12 Biocatalysis in Non-conventional Media 339**
 - 12.1 Enzymes in Organic Solvents 340
 - 12.2 Evidence for the Perceived Advantages of Biocatalysts in Organic Media 341
 - 12.2.1 Advantage 1: Enhancement of Solubility of Reactants 341
 - 12.2.2 Advantage 2: Shift of Equilibria in Organic Media 342
 - 12.2.2.1 Biphasic Reactors 342
 - 12.2.3 Advantage 3: Easier Separation 343
 - 12.2.4 Advantage 4: Enhanced Stability of Enzymes in Organic Solvents 344
 - 12.2.5 Advantage 5: Altered Selectivity of Enzymes in Organic Solvents 344

12.3	State of Knowledge of Functioning of Enzymes in Solvents	344
12.3.1	Range of Enzymes, Reactions, and Solvents	344
12.3.2	The Importance of Water in Enzyme Reactions in Organic Solvents	345
12.3.2.1	Exchange of Water Molecules between Enzyme Surface and Bulk Organic Solvent	345
12.3.2.2	Relevance of Water Activity	346
12.3.3	Physical Organic Chemistry of Enzymes in Organic Solvents	347
12.3.3.1	Active Site and Mechanism	347
12.3.3.2	Flexibility of Enzymes in Organic Solvents	347
12.3.3.3	Polarity and Hydrophobicity of Transition State and Binding Site	348
12.3.4	Correlation of Enzyme Performance with Solvent Parameters	349
12.3.4.1	Control through Variation of Hydrophobicity: log P Concept	350
12.3.4.2	Correlation of Enantioselectivity with Solvent Polarity and Hydrophobicity	350
12.4	Optimal Handling of Enzymes in Organic Solvents	351
12.4.1	Enzyme Memory in Organic Solvents	352
12.4.2	Low Activity in Organic Solvents Compared to Water	353
12.4.3	Enhancement of Selectivity of Enzymes in Organic Solvents	354
12.5	Novel Reaction Media for Biocatalytic Transformations	355
12.5.1	Substrate as Solvent (Neat Substrates): Acrylamide from Acrylonitrile with Nitrile Hydratase	355
12.5.2	Supercritical Solvents	356
12.5.3	Ionic Liquids	356
12.5.4	Emulsions [Manufacture of Phosphatidylglycerol (PG)]	357
12.5.5	Microemulsions	358
12.5.6	Liquid Crystals	358
12.5.7	Ice–Water Mixtures	359
12.5.8	High-Density Eutectic Suspensions	361
12.5.9	High-Density Salt Suspensions	362
12.5.10	Solid-to-Solid Syntheses	363
12.6	Solvent as a Parameter for Reaction Optimization (“Medium Engineering”)	366
12.6.1	Change of Substrate Specificity with Change of ReactionM: Specificity of Serine Proteases	366
12.6.2	Change of Regioselectivity by Organic Solvent Medium	367
12.6.3	Solvent Control of Enantiospecificity of Nifedipines	367
13	Pharmaceutical Applications of Biocatalysis	373
13.1	Enzyme Inhibition for the Fight against Disease	374
13.1.1	Introduction	374
13.1.2	Procedure for the Development of Pharmacologically Active Compounds	376
13.1.3	Process for the Registration of New Drugs	377
13.1.4	Chiral versus Non-chiral Drugs	379

- 13.2 Enzyme Cascades and Biology of Diseases 380
 - 13.2.1 β -Lactam Antibiotics 380
 - 13.2.2 Inhibition of Cholesterol Biosynthesis (in part after Suckling, 1990) 382
 - 13.2.3 Pulmonary Emphysema, Osteoarthritis: Human Leucocyte Elastase (HLE) 385
 - 13.2.4 AIDS: Reverse Transcriptase and HIV Protease Inhibitors 389
- 13.3 Pharmaceutical Applications of Biocatalysis 393
 - 13.3.1 Antiinfectives (see also Chapter 7, Section 7.5.1) 393
 - 13.3.1.1 Cilastatin 393
 - 13.3.2 Anticholesterol Drugs 393
 - 13.3.2.1 Cholesterol Absorption Inhibitors 395
 - 13.3.3 Anti-AIDS Drugs 396
 - 13.3.3.1 Abacavir Intermediate 396
 - 13.3.3.2 Lobucavir Intermediate 397
 - 13.3.3.3 cis-Aminoindanol: Building Block for Indinavir (Crixivan®) 397
 - 13.3.4 High Blood Pressure Treatment 398
 - 13.3.4.1 Biotransformations towards Omapatrilat 398
 - 13.3.4.2 Lipase Reactions to Intermediates for Cardiovascular Therapy 400
- 13.4 Applications of Specific Biocatalytic Reactions in Pharma 402
 - 13.4.1 Reduction of Keto Compounds with Whole Cells 402
 - 13.4.1.1 Trimegestone 402
 - 13.4.1.2 Reduction of Precursor to Carbonic Anhydrase Inhibitor L-685393 404
 - 13.4.1.3 Montelukast 404
 - 13.4.1.4 LY300164 404
 - 13.4.2 Applications of Pen G Acylase in Pharma 406
 - 13.4.2.1 Loracarbef® 406
 - 13.4.2.2 Xemilofibran 406
 - 13.4.3 Applications of Lipases and Esterases in Pharma 407
 - 13.4.3.1 LTD4 Antagonist MK-0571 407
 - 13.4.3.2 Tetrahydrolipstatin 407
- 14 Bioinformatics 413**
 - 14.1 Starting Point: from Consequence (Function) to Sequence 414
 - 14.1.1 Conventional Path: from Function to Sequence 414
 - 14.1.2 Novel Path: from Sequence to Consequence (Function) 414
 - 14.2 Bioinformatics: What is it, Why do we Need it, and Why Now? (NCBI Homepage) 415
 - 14.2.1 What is Bioinformatics? 415
 - 14.2.2 Why do we Need Bioinformatics? 416
 - 14.2.3 Why Bioinformatics Now? 416
 - 14.3 Tools of Bioinformatics: Databases, Alignments, Structural Mapping 418
 - 14.3.1 Available Databases 418
 - 14.3.2 Protein Data Bank (PDB) 418

14.3.3	Protein Explorer	419
14.3.4	ExPASy Server: Roche Applied Science Biochemical Pathways	419
14.3.5	GenBank	419
14.3.6	SwissProt	420
14.3.7	Information on an Enzyme: the Example of dehydrogenases	420
14.3.7.1	Sequence Information	421
14.3.7.2	Structural Information	422
14.4	Applied Bioinformatics Tools, with Examples	422
14.4.1	BLAST	422
14.4.2	Aligning Several Protein Sequences using ClustalW	425
14.4.3	Task: Whole Genome Analysis	427
14.4.4	Phylogenetic Tree	427
14.5	Bioinformatics for Structural Information on Enzymes	429
14.5.1	The Status of Predicting Protein Three-Dimensional Structure	430
14.6	Conclusion and Outlook	431
15	Systems Biology for Biocatalysis	433
15.1	Introduction to Systems Biology	434
15.1.1	Systems Approach versus Reductionism	434
15.1.2	Completion of Genomes: Man, Earthworm, and Others	435
15.2	Genomics, Proteomics, and other -omics	435
15.2.1	Genomics	435
15.2.2	Proteomics	436
15.3	Technologies for Systems Biology	438
15.3.1	Two-Dimensional Gel Electrophoresis (2D PAGE)	438
15.3.1.1	Separation by Chromatography or Capillary Electrophoresis	439
15.3.1.2	Separation by Chemical Tagging	440
15.3.2	Mass Spectroscopy	441
15.3.2.1	MALDI-TOF-MS (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight MS)	444
15.3.2.2	ESI-triple-quadrupole MS	444
15.3.2.3	ESI-MS Using an Ion Trap Analyzer	445
15.3.3	DNA Microarrays	446
15.3.4	Protein Microarrays	447
15.3.5	Applications of Genomics and Proteomics in Biocatalysis	448
15.3.5.1	Lactic Acid Bacteria and Proteomics	448
15.4	Metabolic Engineering	449
15.4.1	Concepts of Metabolic Engineering	449
15.4.2	Examples of Metabolic Engineering	451
16	Evolution of Biocatalytic Function	457
16.1	Introduction	458
16.1.2	Congruence of Sequence, Function, Structure, and Mechanism	460
16.2	Search Characteristics for Relatedness in Proteins	461
16.2.1	Classification of Relatedness of Proteins: the -log Family	461

16.2.2	Classification into Protein Families	464
16.2.3	Dominance of Different Mechanisms	465
16.3	Evolution of New Function in Nature	466
16.3.1	Dual-Functionality Proteins	469
16.3.1.1	Moonlighting Proteins	469
16.3.1.2	Catalytic Promiscuity	469
16.3.2	Gene Duplication	470
16.3.3	Horizontal Gene Transfer (HGT)	471
16.3.4	Circular Permutation	474
16.4	α/β -Barrel Proteins as a Model for the Investigation of Evolution	474
16.4.1	Why Study α/β -Barrel Proteins?	474
16.4.2	Example of Gene Duplication: Mandelate and α -Ketoadipate Pathways	475
16.4.2.1	Description of Function	480
16.4.3	Exchange of Function in the Aromatic Biosynthesis Pathways: Trp and His Pathways	481
17	Stability of Proteins	487
17.1	Summary: Protein Folding, First-Order Decay, Arrhenius Law	488
17.1.1	The Protein Folding Problem	488
17.1.2	Why do Proteins Fold?	489
17.2	Two-State Model: Thermodynamic Stability of Proteins (Unfolding)	491
17.2.1	Protein Unfolding and Deactivation	491
17.2.2	Thermodynamics of Proteins	491
17.3	Three-State Model: Lumry–Eyring Equation	493
17.3.1	Enzyme Deactivation	493
17.3.2	Empirical Deactivation Model	494
17.4	Four-State Model: Protein Aggregation	496
17.4.1	Folding, Deactivation, and Aggregation	496
17.4.2	Model to Account for Competition between Folding and Inclusion Body Formation	498
17.4.2.1	Case 1: In Vitro – Protein Synthesis Unimportant	498
17.4.2.2	Case 2: In Vivo – Protein Synthesis Included	499
17.5	Causes of Instability of Proteins: $\Delta G < 0$, $\gamma(t)$, A	501
17.5.1	Thermal Inactivation	502
17.5.2	Deactivation under the Influence of Stirring	503
17.5.3	Deactivation under the Influence of Gas Bubbles	504
17.5.4	Deactivation under the Influence of Aqueous/Organic Interfaces	505
17.5.5	Deactivation under the Influence of Salts and Solvents	505
17.6	Biotechnological Relevance of Protein Folding: Inclusion Bodies	505
17.7	Summary: Stabilization of Proteins	506
17.7.1	Correlation between Stability and Structure	507

18	Artificial Enzymes	511
18.1	Catalytic Antibodies	512
18.1.1	Principle of Catalytic Antibodies: Connection between Chemistry and Immunology	512
18.1.2	Test Reaction Selection, Haptens, Mechanisms, Stabilization	514
18.1.2.1	Mechanism of Antibody-Catalyzed Reactions	516
18.1.2.2	Stabilization of Charged Transition States	517
18.1.2.3	Effect of Antibodies as Entropy Traps	517
18.1.3	Breadth of Reactions Catalyzed by Antibodies	518
18.1.3.1	Fastest Antibody-Catalyzed Reaction in Comparison with Enzymes	518
18.1.3.2	Antibody-Catalyzed Reactions without Corresponding Enzyme Equivalent	518
18.1.3.3	Example of a Pericyclic Reaction: Claisen Rearrangement	518
18.1.3.4	Antibody Catalysts with Dual Activities	518
18.1.3.5	Scale-Up of an Antibody-Catalyzed Reaction	520
18.1.3.6	Perspective for Catalytic Antibodies	520
18.2	Other Proteinaceous Catalysts: Ribozymes and Enzyme Mimics	521
18.2.1	Ribozymes: RNA World before Protein World?	521
18.2.2	Proteinaceous Enzyme Mimics	521
18.3	Design of Novel Enzyme Activity: Enzyme Models (Synzymes)	523
18.3.1	Introduction	523
18.3.2	Enzyme Models on the Basis of the Binding Step: Diels–Alder Reaction	523
18.3.3	Enzyme Models with Binding and Catalytic Effects	525
18.4	Heterogenized/Immobilized Chiral Chemical Catalysts	526
18.4.1	Overview of Different Approaches	526
18.4.2	Immobilization with Polyamino Acids as Chiral Polymer Catalysts	526
18.4.3	Immobilization on Resins or other Insoluble Carriers	527
18.4.4	Heterogenization with Dendrimers	528
18.4.5	Retention of Heterogenized Chiral Chemical Catalysts in a Membrane Reactor	529
18.4.6	Recovery of Organometallic Catalysts by Phase Change: Liquid–Liquid Extraction	531
18.5	Tandem Enzyme Organometallic Catalysts	532
19	Design of Biocatalytic Processes	539
19.1	Design of Enzyme Processes: High-Fructose Corn Syrup (HFCS)	540
19.1.1	Manufacture of HFCS from Glucose with Glucose Isomerase (GI): Process Details	540
19.1.2	Mathematical Model for the Description of the Enzyme Kinetics of Glucose Isomerase (GI)	541
19.1.3	Evaluation of the Model of the GI Reaction in the Fixed-Bed Reactor	543
19.1.4	Productivity of a Fixed-Bed Enzyme Reactor	547

19.2	Processing of Fine Chemicals or Pharmaceutical Intermediates in an Enzyme Membrane Reactor	549
19.2.1	Introduction	549
19.2.2	Determination of Process Parameters of a Membrane Reactor	550
19.2.2.1	Case 1: Leakage through Membrane, no Deactivation	551
19.2.2.2	Case 2: Leakage through the Membrane and Deactivation of Enzyme	552
19.2.2.3	Design Criterion for EMRs	552
19.2.3	Large-Scale Applications of Membrane Reactors	553
19.2.3.1	Enantiomerically Pure l-Amino Acids for Infusion Solutions and as Building Blocks for New Drugs	553
19.2.3.2	Aqueous–Organic Membrane Reactors	554
19.2.3.3	Other Processes in Enzyme Membrane Reactors	554
19.3	Production of Enantiomerically Pure Hydrophobic Alcohols: Comparison of Different Process Routes and Reactor Configurations	556
19.3.1	Isolated Enzyme Approach	556
19.3.2	Whole-Cell Approach	559
19.3.3	Organometallic Catalyst Approach	561
19.3.4	Comparison of Different Catalytic Reduction Strategies	563
20	Comparison of Biological and Chemical Catalysts for Novel Processes	569
20.1	Criteria for the Judgment of (Bio-)catalytic Processes	570
20.1.1	Discussion: Jacobsen's Five Criteria	570
20.1.2	Comment on Jacobsen's Five Criteria	572
20.2	Position of Biocatalysis in Comparison to Chemical Catalysts for Novel Processes	575
20.2.1	Conditions and Framework for Processes of the Future	575
20.2.2	Ibuprofen (Painkiller)	577
20.2.3	Indigo (Blue Dye)	578
20.2.4	Menthol (Peppermint Flavoring Agent)	580
20.2.4.1	Separation of Diastereomeric Salt Pairs	580
20.2.4.2	Homogeneous Catalysis with Rh-BINAP	580
20.2.4.3	Lipase-Catalyzed Resolution of Racemic Menthol Esters	582
20.2.5	Ascorbic Acid (Vitamin C)	583
20.2.5.1	The Traditional Reichstein–Grüssner Synthesis	584
20.2.5.2	Two-Step Fermentation Process to 2-Ketogulonic Acid with Chemical Step to Ascorbic Acid	584
20.2.5.3	One-Step Fermentation to 2-Ketogulonic Acid with Chemical Step to Ascorbic Acid	585
20.3	Pathway Engineering through Metabolic Engineering	586
20.3.1	Pathway Engineering for Basic Chemicals: 1,3-Propanediol	586
20.3.2	Pathway Engineering for Pharmaceutical Intermediates: cis-Aminoindanol	588

1

Introduction to Biocatalysis

Summary

Over the last 20 years, many reservations with respect to biocatalysis have been voiced, contending that: (i) enzymes only feature limited substrate specificity; (ii) there is only limited availability of enzymes; (iii) only a limited number of enzymes exist; (iv) protein catalyst stability is limited; (v) enzyme reactions are saddled with limited space–time yield; and (vi) enzymes require complicated co-substrates such as cofactors.

Driven by the discovery of many novel enzymes, by recombinant DNA technology which allows both more efficient production and targeted or combinatorial alterations of individual enzymes, and by process development towards higher stability and volumetric productivity, synthesis routes in which one or all of the steps are biocatalytic have advanced dramatically in recent years. Design rules for improved biocatalysts are increasingly precise and easy to use.

Biocatalysts do not operate by different scientific principles from organic catalysts. The existence of a multitude of enzyme models including oligopeptidic or polypeptidic catalysts proves that all enzyme action can be explained by rational chemical and physical principles. However, enzymes can create unusual and superior reaction conditions such as extremely low pK_a values or a high positive potential for a redox metal ion. Enzymes increasingly have been found to catalyze almost any reaction of organic chemistry.

Biotechnology and biocatalysis differ from conventional processes not only by featuring a different type of catalyst; they also constitute a new technology base. The *raw materials base* of a biologically-based process is built on sugar, lignin, or animal or plant wastes; in biotechnology, unit operations such as membrane processes, chromatography, or biocatalysis are prevalent, and the product range of biotechnological processes often encompasses chiral molecules or biopolymers such as proteins, nucleic acids or carbohydrates.

Cost and margin pressure from less expensive competitors and operation with emphasis on a clean (or less polluted) environment are two major developments. Fewer processing steps, with higher yields at each step, lower material and energy costs, and less waste are the goals. Biotechnology and biocatalysis often offer unique technology options and solutions, they act as *enabling technologies*; in other cases, biocatalysis has to outperform competing technologies to gain access. In the phar-

maceutical industry, the reason for the drive for enantiomeric purity is that the vast majority of novel drugs are chiral targets, favoring biocatalysis as the technology with the best selectivity performance.

Biocatalytic processes increasingly penetrate the chemical industry. In a recent study, 134 industrial-scale biotransformations, on a scale of > 100 kg with whole cells or enzymes starting from a precursor other than a C-source, were analyzed. Hydrolases (44%), followed by oxido-reductases (30%), dominate industrial biocatalytic applications. Average performance data for fine chemicals (not pharmaceuticals) applications are 78% yield, a final product concentration of 108 g L⁻¹, and a volumetric productivity of 372 g (L · d)⁻¹.

1.1

Overview: The Status of Biocatalysis at the Turn of the 21st Century

1.1.1

State of Acceptance of Biocatalysis

Over the last 20 years, many reservations with respect to biocatalysis have been voiced. The critics, often focusing on the drawbacks, have contended that

- enzymes only feature limited substrate specificity,
- there is only limited availability of enzymes,
- only a limited number of enzymes exist,
- protein catalyst stability is limited,
- enzyme reactions are saddled with limited space–time yield, and
- enzymes require complicated co-substrates such as cofactors.

The renaissance of biocatalysis, supported by the advent of recombinant DNA, is only about 20 years old. Recently, several publications have appeared which deal specifically with the attitudes listed above (Rozzell, 1999; Bommarius, 2001; Rasor, 2001). Most of the points above can either be refuted or they can be levied against any novel catalytic technology; the situation with some competing technologies such as chiral homogeneous catalysts is similar to that with enzymes (Chapters 18 and 20).

- *Enzymes only feature limited substrate specificity.* Often, enzymes designed to convert small molecules such as hydrogen peroxide, urea, fumaric acid, or L-aspartic acid feature extremely narrow substrate specificity; the corresponding enzymes catalase, urease, fumarase or aspartase, and L-aspartate decarboxylase take either few other substrates, such as alkyl peroxides in the case of catalase, or no other substrate, such as urease, which only converts urea. On the other hand, very large enzymes acting as multi-enzyme complexes such as nonribosomal peptide synthetases (NRPSs) (Kleinkauf, 1996) are often highly specific. Ordinary-sized enzymes working on medium-sized substrates, however, in most cases feature broad substrate specificity, a fact already noted by Rasor and Voss (Rasor, 2001).

- *There is only limited availability of enzymes.* Until very recently, limited availability of enzymes was indeed a major problem. About ten years ago, with 3196 different enzymes already listed in Enzyme Nomenclature (Moss, 1992), only about 50 enzymes were fully characterized and only about a dozen enzymes available commercially on a regular basis. However, recombinant DNA technology, discovered in 1978 by Cohen and Boyer (Stanford University, Palo Alto, CA, USA), over the next 20 years allowed enzymes to be produced much more efficiently, in higher purity, and more inexpensively (Baneyx, 1999), so that today a multitude of enzymes are available not only from established suppliers such as Sigma–Aldrich–Fluka (Milwaukee, WI, USA), E. Merck (Darmstadt, Germany), Mercian (Tokyo, Japan), or Roche Diagnostics (Mannheim, Germany) but increasingly also from smaller, more focused suppliers such as Biocatalytics (Pasadena, CA, USA) or Jülich Fine Chemicals (Jülich, Germany). The argument of unavailability or scarcity will be less and less justified in the future.
- *Only a limited number of enzymes exist.* This criticism, while depending on the observer’s position, is indeed a drawback at the moment. Although enzymes have been found for every conceivable organic chemical reaction except the hetero-Cope rearrangement (Table 1.4, below), there are enzymes sought for many more reactions than there are enzymes available. If enzymes were inferior catalysts this situation would not arise, of course. In fact, enzymes are often superior catalysts (see the next section), so superior is fact, that the community seeks plenty more of them. Chapter 3 treats the discovery of novel enzymes, whereas Chapters 10 and 11 cover improvement of existing enzymes through rational (protein engineering) and combinatorial random mutagenesis (directed evolution).
- *Protein catalyst stability is limited.* This is one of major drawbacks of enzymes. They commonly require temperatures around ambient to perform (15–50°C), pH values around neutral (pH 5–9), and aqueous media. In addition, any number of system components or features such as salts, inhibitors, liquid–gas or liquid–solid interfaces, or mechanical stress can slow down or deactivate enzymes. Under almost any condition, native proteins, with their Gibbs free enthalpy of stability of just a few kilojoules per mole, are never far away from instability. In this book, we cover inhibitors (Chapter 5, Section 5.3) or impeding system parameters (Chapter 17) and successful attempts at broadening the choice of solvents (Chapter 12).
- *Enzyme reactions are saddled with limited space–time yield.* The notion that biocatalysts are slow catalysts is false. Slow catalysts, applied at low concentrations, certainly lead to low space–time yields. However, optimized syntheses not only produce very good selectivities or total turnover numbers but also satisfactory to excellent space–time yields. Examples with such good s.t.y. values are – in commodity biochemicals, the synthesis of L-aspartate from fumaric acid and ammonia with space–time-yields of up to 60 kg (L · d)^{–1} (Rozzell, 1999), and

- in advanced pharmaceutical intermediates, kinetically-controlled peptide synthesis to kyotorphin (Tyr-Arg) catalyzed by α -chymotrypsin from maleyl-L-Tyr-OEt and Arg-OEt, employing a highly soluble protecting group at the electrophile (Fischer, 1994). Space–time-yields of $1.34 \text{ kg (L} \cdot \text{d)}^{-1}$ have been achieved.

The question of high volumetric productivity is coupled to the solubility of substrates. High space–time-yields have been demonstrated to be correlated with high solubilities of substrates (Bommarius, 2001).

- *Enzymes require complicated co-substrates such as cofactors.* Much has been made of the requirement of some enzymes for cofactors, such as nicotinamide-containing compounds, NAD(P)(H), for dehydrogenases; flavin compounds, FMN or FAD, for oxidases; pyridoxylphosphate, PLP, for transaminases and decarboxylases; thiamine pyrophosphate, TPP, for carboligases, and vitamin B12 for glycerate dehydratase, among others. The scale-up of L-aspartate decarboxylation to L-alanine with the help of PLP-requiring L-aspartate decarboxylase, or of reductive amination of trimethylpyruvate to L-tert-leucine with the help of NADH-requiring leucine dehydrogenase demonstrates the feasibility of industrial processing with cofactor-requiring enzymes. The implementation also gives credence to the suggestion that cofactors are no longer the dominating cost component, as was believed until recently. Requirements for cofactors constitute a technological challenge but one that has been met successfully and so should not be regarded as impeding the use of biocatalysts in processing.

1.1.2

Current Advantages and Drawbacks of Biocatalysis

1.1.2.1 Advantages of Biocatalysts

The biggest advantage of enzymes is their often unsurpassed selectivity. While enzymes are used beneficially to increase chemical selectivity or regioselectivity of a reaction, their biggest advantage lies in the differentiation between enantiomeric substrates, a pair of substrates with Gibbs free enthalpy differences between the *R*- and the *S*-enantiomer ΔG_{RS} of around $1\text{--}3 \text{ kJ mol}^{-1}$. With enzymes, enantioselectivities of $> 99\%$ e.e. can be achieved routinely, although by no means in every case. This fact becomes increasingly important for using biocatalysts in the synthesis of advanced pharmaceutical intermediates, as regulatory agencies require separate toxicological studies for every impurity comprising above 1% of the content (Chapter 13, Section 13.1.4) (Crossley, 1995).

The fact that enzymes are active mostly at mild, near-ambient conditions of temperature and pH and preferentially in aqueous media is often regarded as an advantage rather than a drawback nowadays. Goals for industrial processing such as “sustainable development”, “green chemistry”, or “environmentally benign manufacturing”, an increasingly important boundary condition for industrial activity in a large part of the world, would be much harder to attain without the availability of biocatalysts which tolerate and require such conditions.